ClinicalTrials.gg
CompletedNCT05216263ATO-BOTOXUpdated Jun 16, 2026Results posted

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

A Phase 3 interventional study of Atogepant in Chronic Migraine, sponsored by AbbVie. Completed at 29 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
19th of 21
75 · median 468
Started
2022
with 1 other
Phase 3
15 of 21
3 open now
Registered
11th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 15 in phase 3, and was the 11th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored.

Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 adult participants will be enrolled at approximately 30 sites in the United States.

All participants will receive atogepant oral tablet once a day (QD) during the 24-week treatment period, in addition to their standard of care Botox.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Chronic Migraine

Browse trials for

Keywords

  • Chronic Migraine
  • Migraine
  • Atogepant
  • OnabotulinumtoxinA
  • BOTOX
  • QULIPTA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of chronic migraine (CM), with or without aura, consistent with a diagnosis according to International Classification of Headache Disorders 3rd edition (ICHD-3 2018) and with or without acute medication overuse as defined in the protocol.
  • Must be currently treated with BOTOX for CM: treated with >= 2 treatment cycles in the 8 months prior to Visit 2 (Day 1) with documentation of payer authorization or written attestation of self-pay to support continued use of BOTOX.
  • Must have 8 to 23 (inclusive) migraine days in the electronic diary [eDiary] screening/baseline period (eDiary data must have been collected for at least 20 days).

Exclusion criteria

Exclusion Criteria:

  • Use of opioid-containing products for more than 4 days per month for acute treatment of headache in the 3 months prior to Screening or during the screening/baseline period.
  • Treatment of study target muscles using acupuncture, transcutaneous electrical nerve stimulation (TENS), cranial traction, dental splints for headache, or head and/or neck injections of anesthetics/ within 4 weeks prior to Screening and throughout the study.
  • Concurrent use of any migraine prevention treatment other than BOTOX (required concomitant medication; or topiramate \<=100mg daily) including use of oral gepants in the 4 weeks prior to screening nor during the screening/baseline period.
  • Current use or use within the 6 months (24 weeks) prior to Screening, of mAbs blocking the CGRP pathway.
  • Concurrent use of oral gepants for acute migraine treatment in the 4 weeks prior to screening nor during the screening/baseline period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Atogepant

    Participants received atogepant 60 mg once a day (QD) during the 24-week treatment period.

    Drug: Atogepant

Interventions

  • Oral Tablet

    Also known as: QULIPTA

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 4 weeks following last dose of study drug (up to 28 weeks)

  2. Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator

    Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis. Glomerular Filtration Rate (GFR) is a clinical measurement that calculates how many milliliters of blood the kidneys filter every second. Glucose, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of sugar. Protein, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of protein.

    Time frame: From first dose of study drug until last dose of study drug (24 weeks)

  3. Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

    Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting\], pulse rate \[sitting\], and weight. Number of participants with non-PCS baseline values who met the PCS criterion at least once post-baseline are reported.

    Time frame: From first dose of study drug until last dose of study drug (24 weeks)

  4. Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

    Time frame: From first dose of study drug until last dose of study drug (24 weeks)

  5. Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

    12-lead ECGs were performed at select study visits.

    Time frame: From first dose of study drug until last dose of study drug (24 weeks)

07

Results

Posted Jun 16, 2026

Participant flow

The screening/baseline period was up to 12 weeks, which included at least 28 days of eDiary collection of migraine days and headache days at the end of the screening/baseline period.

Participant flow — Overall Study
MilestoneAll Participants
Started75
Completed57
Not completed18
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject11
Withdrew: Other4

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 4 weeks following last dose of study drug (up to 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAll Participants
Any Treatment-emergent Adverse Event (TEAE)49
AE with reasonable possibility of being related to atogepant22
AE with reasonable possibility of being related to BOTOX1
Any severe TEAE2
Any Treatment-emergent Serious Adverse Event (TESAE)2
AE leading to withdrawal of atogepant study treatment7
AE leading to withdrawal of BOTOX treatment2
Any TEAE leading to death0
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator

Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis. Glomerular Filtration Rate (GFR) is a clinical measurement that calculates how many milliliters of blood the kidneys filter every second. Glucose, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of sugar. Protein, Urinalysis: At least 1+ indicates that the urine contains an increased concentration of protein.

Time frame:
From first dose of study drug until last dose of study drug (24 weeks)
Reported as:
Number · number of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator
number of participantsAll Participants
Basophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0
Eosinophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0
Erythrocytes, Hematology (10^12/L): < 0.9 x Lower Limit of Normal (LLN)1
Erythrocytes, Hematology (10^12/L): > 1.1 x Upper Limit of Normal (ULN)0
Hematocrit (RATIO): < 0.9 x Lower Limit of Normal (LLN)0
Hematocrit (RATIO): > 1.1 x Upper Limit of Normal (ULN)0
Hemoglobin (g/L): < 0.9 x Lower Limit of Normal (LLN)0
Hemoglobin (g/L): > 1.1 x Upper Limit of Normal (ULN)0
Leukocytes, Hematology (10^9/L): < 0.9 x Lower Limit of Normal (LLN)1
Leukocytes, Hematology (10^9/L): > 1.5 x Upper Limit of Normal (ULN)0
Lymphocytes (10^9/L): < 0.7 x Lower Limit of Normal (LLN)2
Lymphocytes (10^9/L): > 1.3 x Upper Limit of Normal (ULN)0
Monocytes (10^9/L): < 0.5 x Lower Limit of Normal (LLN)0
Monocytes (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0
Neutrophils (10^9/L): < 0.7 x Lower Limit of Normal (LLN)1
Neutrophils (10^9/L): > 1.3 x Upper Limit of Normal (ULN)2
Platelets (10^9/L): < 0.5 x Lower Limit of Normal (LLN)0
Platelets (10^9/L): > 1.5 x Upper Limit of Normal (ULN)0
Alanine Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)0
Albumin (g/L): < 0.8 x Lower Limit of Normal (LLN)0
Albumin (g/L): > 1.2 x Upper Limit of Normal (ULN)0
Alkaline Phosphatase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)0
Aspartate Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)0
Bicarbonate (mmol/L): < 0.9 x Lower Limit of Normal (LLN)3
Bicarbonate (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0
Bilirubin, Chemistry (umol/L): ≥ 1.5 x Upper Limit of Normal (ULN)0
Calcium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0
Calcium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0
Chloride (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0
Chloride (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0
Cholesterol (mmol/L): > 1.6 x Upper Limit of Normal (ULN)0
Creatine Kinase (U/L): > 2.0 x Upper Limit of Normal (ULN)4
Creatinine (umol/L): > 1.5 x Upper Limit of Normal (ULN)0
Glomerular Filtration Rate, Estimated (mL/sec/1.73m^2): < 1 mL/sec/1.73m^24
Glucose, Chemistry (mmol/L): < 0.8 x Lower Limit of Normal (LLN)3
Glucose, Chemistry (mmol/L): > 2.0 x Upper Limit of Normal (ULN)1
Lactate Dehydrogenase (U/L): > 3.0 x Upper Limit of Normal (ULN)0
Phosphate (mmol/L): < 0.9 x Lower Limit of Normal (LLN)1
Phosphate (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0
Potassium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0
Potassium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)1
Protein, Chemistry (g/L): < 0.9 x Lower Limit of Normal (LLN)1
Protein, Chemistry (g/L): > 1.1 x Upper Limit of Normal (ULN)0
Sodium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0
Sodium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0
Urate (umol/L): > 1.2 x Upper Limit of Normal (ULN)0
Urea Nitrogen (mmol/L): > 1.5 x Upper Limit of Normal (ULN)0
Glucose, Urinalysis: At least 1+2
Protein, Urinalysis: At least 1+16
Specific Gravity: > 1.1 x Upper Limit of Normal (ULN)0
pH: < 0.9 x Lower Limit of Normal (LLN)0
pH: > 1.1 x Upper Limit of Normal (ULN)0
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting\], pulse rate \[sitting\], and weight. Number of participants with non-PCS baseline values who met the PCS criterion at least once post-baseline are reported.

Time frame:
From first dose of study drug until last dose of study drug (24 weeks)
Reported as:
Number · number of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
number of participantsAll Participants
Sitting Systolic Blood Pressure (mmHg): ≥ 180 and increase from Baseline of ≥ 200
Sitting Systolic Blood Pressure (mmHg): ≤ 90 and decrease from Baseline of ≥ 200
Sitting Diastolic Blood Pressure (mmHg): ≥ 105 and increase from Baseline of ≥ 151
Sitting Diastolic Blood Pressure (mmHg): ≤ 50 and decrease from Baseline of ≥ 151
Sitting Pulse Rate (bpm): ≥ 120 and increase from Baseline of ≥ 150
Sitting Pulse Rate (bpm): ≤ 50 and decrease from baseline of ≥ 150
Weight (kg): Increase from Baseline of ≥ 7%6
Weight (kg): Decrease from Baseline of ≥ 7%6
PrimaryPercentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

Time frame:
From first dose of study drug until last dose of study drug (24 weeks)
Reported as:
Number · number of participants
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
number of participantsAll Participants
No suicidal ideation73
Suicidal ideation0
Most severe suicidal ideation: Active suicidal ideation with specific plan and intent0
Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan0
Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act0
Most severe suicidal ideation: Non-specific active suicidal thoughts0
Most severe suicidal ideation: Wish to be dead0
No suicidal behavior73
Suicidal behavior0
Most severe suicidal behavior: Actual attempt0
Most severe suicidal behavior: Interrupted attempt0
Most severe suicidal behavior: Aborted attempt0
Most severe suicidal behavior: Preparatory acts or behavior0
Completed Suicide0
Non-suicidal self-injurious behavior1
PrimaryPercentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

12-lead ECGs were performed at select study visits.

Time frame:
From first dose of study drug until last dose of study drug (24 weeks)
Reported as:
Number · number of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
number of participantsAll Participants
PR Interval (msec): ≥ 2500
QRS Interval (msec): ≥ 1500
QTcF Interval (msec): > 5000
QTcF Interval (msec): Increase from Baseline of > 600

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time on follow-up was 225 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/75 (0%)2/75 (2.7%)29/75 (38.7%)
Most frequent serious events
Most frequent serious events
EventAll Participants
HAEMATEMESISGastrointestinal disorders1/75
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/75
Most frequent other events
Most frequent other events
EventAll Participants
CONSTIPATIONGastrointestinal disorders12/75
NAUSEAGastrointestinal disorders10/75
URINARY TRACT INFECTIONInfections and infestations6/75
DECREASED APPETITEMetabolism and nutrition disorders5/75
COVID-19Infections and infestations4/75

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)All Participants
Mean47.7 ± 13.68
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female67
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino6
Not Hispanic or Latino69
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White73
More than one race0
Unknown or Not Reported0
08

Study locations

29 sites
  • Neurology and Neurodiagnostics of Alabama /ID# 242538
    Hoover, Alabama 35244-5700, United States
  • Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 241812
    Phoenix, Arizona 85013, United States
  • Arkansas Clinical Research /ID# 241789
    Little Rock, Arkansas 72205, United States
  • Hope Clinical Research /ID# 241772
    Canoga Park, California 91303, United States
  • Profound Research LLC /ID# 244084
    Carlsbad, California 92011-4213, United States
  • Neuro Pain Medical Center /ID# 241992
    Fresno, California 93710, United States
  • Neurological Research Institute /ID# 242688
    Santa Monica, California 90404, United States
  • Neurology Offices of South Florida, PLLC /ID# 242693
    Boca Raton, Florida 33428-2231, United States
  • Coastal Clinical Research Specialists /ID# 247992
    Jacksonville Beach, Florida 32250-1694, United States
  • University of Miami /ID# 252230
    Miami, Florida 33136, United States
  • First Physicians Group - Waldemere /ID# 242861
    Sarasota, Florida 34239-2943, United States
  • Kansas Institute of Research /ID# 241796
    Overland Park, Kansas 66211-1363, United States
  • Duplicate_Ochsner Clinic Foundation /ID# 241803
    Covington, Louisiana 70433-8107, United States
  • Beth Israel Deaconess Medical Center /ID# 241800
    Boston, Massachusetts 02215-5400, United States
  • Michigan Headache & Neurological Institute (MHNI) /ID# 241784
    Ann Arbor, Michigan 48104-5131, United States
  • Minneapolis Clinic of Neurology - Burnsville /ID# 241994
    Burnsville, Minnesota 55337-6732, United States
  • Albany Medical College /ID# 242757
    Albany, New York 12208, United States
  • Dent Neurologic Institute - Amherst /ID# 241776
    Amherst, New York 14226, United States
  • Headache Wellness Center /ID# 241791
    Greensboro, North Carolina 27405, United States
  • Jefferson Hospital for Neuroscience /ID# 243712
    Philadelphia, Pennsylvania 19107-5191, United States
  • Preferred Primary Care Physicians - Jacob Murphy /ID# 241798
    Uniontown, Pennsylvania 15401, United States
  • Chattanooga Medical Research /ID# 253295
    Chattanooga, Tennessee 37404-3239, United States
  • Nashville Neuroscience Group /ID# 243592
    Nashville, Tennessee 37203, United States
  • Texas Neurology /ID# 241795
    Dallas, Texas 75214, United States
  • Inova Health System /ID# 252242
    Falls Church, Virginia 22042, United States
  • Integrated Neurology Services - Falls Church /ID# 244747
    Falls Church, Virginia 22043-2367, United States
  • Puget Sound Neurology /ID# 241787
    Tacoma, Washington 25328, United States
  • Frontier Clinical Research - Kingwood /ID# 242928
    Kingwood, West Virginia 26537-9797, United States
  • West Virginia Univ School Med /ID# 252869
    Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Rothrock J, Najib U, Ailani J, Ashina S, Bao J, Smith JH, Adams AM, Dabruzzo B, Pfleeger K, Blumenfeld A. Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study. Cephalalgia. 2026 Apr;46(4):3331024261429118. doi: 10.1177/03331024261429118. Epub 2026 Apr 7. PubMed 41944477 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2025, 37 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 37 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Jan 31, 2022
StartActual
Mar 22, 2022
Primary completionActual
May 2, 2025
CompletionActual
May 2, 2025
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05216263
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Mar 22, 2022
Primary completion
May 2, 2025
Completion
May 2, 2025
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion